Abramson Cancer Center provides thorough evaluations, diagnoses and treatment plans for chronic myelomonocytic leukemia (CMML), a cancer of the blood and considered to be one of the myelodysplastic/myeloproliferative neoplasms (MDS/MPN).
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are a type of chronic blood cancer in which a person's bone marrow does not make blood effectively. MDS/MPN have both "dysplastic" and "proliferative" features that cannot be classified as either myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPN), and for this reason have been categorized as an overlap syndrome with its own distinct characteristics (MDS/MPN).
Chronic myelomonocytic leukemia (CMML) is cancer of the blood, and is considered to be one of the myelodysplastic/myeloproliferative neoplasms. CMML can be treated by our Leukemia Program.
Every step of cancer treatment, from a cancer diagnosis and treatment, to forming a survivorship plan, comes with different needs and issues that should be addressed.
Oncology navigators are committed to making sure every patient experience is as comfortable as possible. They are experts in navigating complex health care situations and serve as a consistent point of contact and a reliable source for advice, support and direction for patients and families.